![These highlights do not include all the information needed to use STELARA® safely and effectively. See full prescribing information for STELARA®. STELARA® (ustekinumab) injection, for subcutaneous or intravenous use Initial U.S. Approval: These highlights do not include all the information needed to use STELARA® safely and effectively. See full prescribing information for STELARA®. STELARA® (ustekinumab) injection, for subcutaneous or intravenous use Initial U.S. Approval:](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=stelara-01.jpg&id=659119)
These highlights do not include all the information needed to use STELARA® safely and effectively. See full prescribing information for STELARA®. STELARA® (ustekinumab) injection, for subcutaneous or intravenous use Initial U.S. Approval:
![Infant Ustekinumab Clearance, Risk of Infection, and Development After Exposure During Pregnancy - Clinical Gastroenterology and Hepatology Infant Ustekinumab Clearance, Risk of Infection, and Development After Exposure During Pregnancy - Clinical Gastroenterology and Hepatology](https://www.cghjournal.org/cms/asset/604d5693-6e40-4a85-af57-c67b7fbc374a/ga1.jpg)
Infant Ustekinumab Clearance, Risk of Infection, and Development After Exposure During Pregnancy - Clinical Gastroenterology and Hepatology
![Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial - The Lancet Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial - The Lancet](https://www.thelancet.com/cms/asset/05ed1fe6-994c-4afe-be19-f43d50742925/gr1.jpg)
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial - The Lancet
![Frontiers | Biologics During Pregnancy and Breastfeeding Among Women With Rheumatic Diseases: Safety Clinical Evidence on the Road Frontiers | Biologics During Pregnancy and Breastfeeding Among Women With Rheumatic Diseases: Safety Clinical Evidence on the Road](https://www.frontiersin.org/files/Articles/621247/fphar-12-621247-HTML-r1/image_m/fphar-12-621247-g001.jpg)